Han Ly1, Nirmal Verma1, Fengen Wu1, Miao Liu1, Kathryn E Saatman2,3, Peter T Nelson4, John T Slevin5,6, Larry B Goldstein6, Geert Jan Biessels7, Florin Despa1,6. 1. Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY. 2. Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY. 3. Department of Physiology, University of Kentucky, Lexington, KY. 4. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY. 5. Veterans Administration Medical Center, Lexington, KY. 6. Department of Neurology, University of Kentucky, Lexington, KY. 7. Department of Neurology, University Medical Center Utrecht, Utrecht, the Netherlands.
Abstract
OBJECTIVE: The brain blood vessels of patients with type 2 diabetes and dementia have deposition of amylin, an amyloidogenic hormone cosecreted with insulin. It is not known whether vascular amylin deposition is a consequence or a trigger of vascular injury. We tested the hypothesis that the vascular amylin deposits cause endothelial dysfunction and microvascular injury and are modulated by amylin transport in the brain via plasma apolipoproteins. METHODS: Rats overexpressing amyloidogenic (human) amylin in the pancreas (HIP rats) and amylin knockout (AKO) rats intravenously infused with aggregated amylin were used for in vivo phenotyping. We also carried out biochemical analyses of human brain tissues and studied the effects of the aggregated amylin on endothelial cells ex vivo. RESULTS: Amylin deposition in brain blood vessels is associated with vessel wall disruption and abnormal surrounding neuropil in patients with type 2 diabetes and dementia, in HIP rats, and in AKO rats infused with aggregated amylin. HIP rats have brain microhemorrhages, white matter injury, and neurologic deficits. Vascular amylin deposition provokes loss of endothelial cell coverage and tight junctions. Intravenous infusion in AKO rats of human amylin, or combined human amylin and apolipoprotein E4, showed that amylin binds to plasma apolipoproteins. The intravenous infusion of apolipoprotein E4 exacerbated the brain accumulation of aggregated amylin and vascular pathology in HIP rats. INTERPRETATION: These data identify vascular amylin deposition as a trigger of brain endothelial dysfunction that is modulated by plasma apolipoproteins and represents a potential therapeutic target in diabetes-associated dementia and stroke. Ann Neurol 2017;82:208-222.
OBJECTIVE: The brain blood vessels of patients with type 2 diabetes and dementia have deposition of amylin, an amyloidogenic hormone cosecreted with insulin. It is not known whether vascular amylin deposition is a consequence or a trigger of vascular injury. We tested the hypothesis that the vascular amylin deposits cause endothelial dysfunction and microvascular injury and are modulated by amylin transport in the brain via plasma apolipoproteins. METHODS:Rats overexpressing amyloidogenic (human) amylin in the pancreas (HIP rats) and amylin knockout (AKO) rats intravenously infused with aggregated amylin were used for in vivo phenotyping. We also carried out biochemical analyses of human brain tissues and studied the effects of the aggregated amylin on endothelial cells ex vivo. RESULTS:Amylin deposition in brain blood vessels is associated with vessel wall disruption and abnormal surrounding neuropil in patients with type 2 diabetes and dementia, in HIP rats, and in AKO rats infused with aggregated amylin. HIP rats have brain microhemorrhages, white matter injury, and neurologic deficits. Vascular amylin deposition provokes loss of endothelial cell coverage and tight junctions. Intravenous infusion in AKO rats of humanamylin, or combined humanamylin and apolipoprotein E4, showed that amylin binds to plasma apolipoproteins. The intravenous infusion of apolipoprotein E4 exacerbated the brain accumulation of aggregated amylin and vascular pathology in HIP rats. INTERPRETATION: These data identify vascular amylin deposition as a trigger of brain endothelial dysfunction that is modulated by plasma apolipoproteins and represents a potential therapeutic target in diabetes-associated dementia and stroke. Ann Neurol 2017;82:208-222.
Authors: Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery Journal: Biochim Biophys Acta Date: 2008-08-22
Authors: Frederick A Schmitt; Peter T Nelson; Erin Abner; Stephen Scheff; Gregory A Jicha; Charles Smith; Gregory Cooper; Marta Mendiondo; Deborah D Danner; Linda J Van Eldik; Allison Caban-Holt; Mark A Lovell; Richard J Kryscio Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: Erin L Abner; Peter T Nelson; Richard J Kryscio; Frederick A Schmitt; David W Fardo; Randall L Woltjer; Nigel J Cairns; Lei Yu; Hiroko H Dodge; Chengjie Xiong; Kamal Masaki; Suzanne L Tyas; David A Bennett; Julie A Schneider; Zoe Arvanitakis Journal: Alzheimers Dement Date: 2016-01-23 Impact factor: 21.566
Authors: Sanda Despa; Savita Sharma; Todd R Harris; Hua Dong; Ning Li; Nipavan Chiamvimonvat; Heinrich Taegtmeyer; Kenneth B Margulies; Bruce D Hammock; Florin Despa Journal: J Am Heart Assoc Date: 2014-08-21 Impact factor: 5.501
Authors: Nirmal Verma; Miao Liu; Han Ly; Analia Loria; Kenneth S Campbell; Heather Bush; Philip A Kern; Pedro A Jose; Heinrich Taegtmeyer; Donald M Bers; Sanda Despa; Larry B Goldstein; Andrew J Murray; Florin Despa Journal: Kidney Int Date: 2019-09-05 Impact factor: 10.612
Authors: Ling Wu; Paul Velander; Anne M Brown; Yao Wang; Dongmin Liu; David R Bevan; Shijun Zhang; Bin Xu Journal: ACS Pharmacol Transl Sci Date: 2021-07-21
Authors: Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Jennifer L Dearborn; Anna M Kucharska-Newton; Juebin Huang; Alvaro Alonso; Rebecca F Gottesman Journal: JAMA Neurol Date: 2018-11-01 Impact factor: 18.302